Muromonab-cd3
Muromonab-cd3 is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against T-cell surface glycoprotein CD3 epsilon chain.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| immune system diseases | D007154 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J7505 | Muromonab-cd3, parenteral, 5 mg |
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | D46 | — | 3 | — | — | — | 3 | |
| Leukemia | D007938 | C95 | 1 | 3 | — | — | — | 3 | |
| Lymphoma | D008223 | C85.9 | 2 | 2 | — | — | — | 3 | |
| Hodgkin disease | D006689 | C81 | 1 | 2 | — | — | — | 2 | |
| Hematologic neoplasms | D019337 | 2 | 1 | — | — | — | 2 | ||
| Graft vs host disease | D006086 | D89.81 | — | 2 | — | — | — | 2 | |
| Myocarditis | D009205 | I51.4 | — | 1 | — | — | 1 | 2 | |
| Plasma cell neoplasms | D054219 | 1 | 1 | — | — | — | 2 | ||
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | 1 | — | — | — | 2 |
| Central nervous system neoplasms | D016543 | 1 | 1 | — | — | — | 2 |
Show 19 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | — | — | — | 1 |
| Kaposi sarcoma | D012514 | C46 | 1 | — | — | — | — | 1 | |
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MUROMONAB-CD3 |
| INN | muromonab-cd3 |
| Description | Muromonab-CD3 (mouse mab) |
| Classification | Antibody |
| Drug class | cannabinol derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 140608-64-6 |
| RxCUI | 42405 |
| ChEMBL ID | CHEMBL1201608 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00075 |
| UNII ID | JGA39ICE2V (ChemIDplus, GSRS) |
Target
Agency Approved
CD3E
CD3E
Organism
Homo sapiens
Gene name
CD3E
Gene synonyms
T3E
NCBI Gene ID
Protein name
T-cell surface glycoprotein CD3 epsilon chain
Protein synonyms
CD3-epsilon, CD3e, CD3e antigen, epsilon polypeptide (TiT3 complex), CD3e molecule, epsilon (CD3-TCR complex), T-cell antigen receptor complex, epsilon subunit of T3, T-cell surface antigen T3/Leu-4 epsilon chain
Uniprot ID
Mouse ortholog
Cd3e (12501)
T-cell surface glycoprotein CD3 epsilon chain (P22646)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more